- Funding period:
01.03.2018 - 28.02.2020
- Project description:
The aim is to develop novel human anti-ErbB4 antibodies, which in combination with a humanized anti-EGFR antibody derived from Cetuximab, or as bispecific EGFRxErbB4-targeting antibodies, can be used for the treatment of cancer patients with EGFR- and ErbB4-dependant tumors. At the end of the two-year project, a lead candidate for further preclinical and clinical development as well as information on patient stratification will be available.
- Yumab GmbH (Braunschweig), Dr. Thomas Schirrmann
- Center of Research and Technological Assistance of Jalisco (CIATEJ), Dr. Mario Alberto Flores und Dr. Abel Gutierrez
- RD biotec S.A de C.V (Dr. Marleby García González)
- Preclinical Unit of Investigation (UNIPREC), Dr. Isabela Gracia